Forty years ago, cannabis was labelled "a Gateway Drug" to harder drug use -- such as psychedelics. Today, cannabis is the Gateway Drug to psychedelics legalization.
The Mental Health Crisis: A Pandemic Becomes A Catastrophe
Two pandemics are currently afflicting the planet. While our governments focus on the smaller one (COVID-19), the larger one (the Mental Health Crisis) is rapidly spiralling out of control.
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
MINDCURE increases its strategic investment in ATMA Journey Centers and deploys its iSTRYM digital therapeutics platform.
Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical
Mydecine announces several steps in its drug R&D, including four new novel drug candidates.
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai acquires a majority stake in Delaware-based Psyber, Inc., which has a strong focus on digital therapeutics.
Psychedelic Stocks Primed For atai-MindMed Bounce
Both the atai Life Sciences IPO and a MindMed uplisting to the NASDAQ are highly anticipated events. They could occur within weeks -- or even days -- of each other.
Hard Numbers On The Huge Potential Of Psychedelic Drug Development
Drug development is expensive. It is also EXTREMELY lucrative. We take a close look at this revenue potential.
Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement
Institutional interest in psychedelics-based TBI research increases, as Wesana closes an oversubcribed CAD$16.1 million financing.
Cashed-Up Psychedelic Stocks Well Prepared For Adverse Market Conditions
Psychedelic stocks have been hammered in recent weeks by general selling pressures on tech stocks. But with corporate coffers full, these companies can weather the storm.
MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS
MindMed files a "Base Shelf Prospectus" with the SEC.
MINDCURE (CSE: MCUR | OTC: MCURF) Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients
Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 20281
Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe
Cybin announces senior management changes as it moves into the next stage of its evolution.
